These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1013 related articles for article (PubMed ID: 9293807)

  • 1. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Baldwin RM; Zoghbi S; Zea-Ponce Y; Charney DS; van Dyck CH; Hoffer PB; Innis RB
    J Nucl Med; 1997 Sep; 38(9):1453-9. PubMed ID: 9293807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reproducibility of iodine-123-beta-CIT SPECT brain measurement of dopamine transporters.
    Seibyl JP; Laruelle M; van Dyck CH; Wallace E; Baldwin RM; Zoghbi S; Zea-Ponce Y; Neumeyer JL; Charney DS; Hoffer PB; Innis RB
    J Nucl Med; 1996 Feb; 37(2):222-8. PubMed ID: 8667048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
    J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.
    Booij J; Habraken JB; Bergmans P; Tissingh G; Winogrodzka A; Wolters EC; Janssen AG; Stoof JC; van Royen EA
    J Nucl Med; 1998 Nov; 39(11):1879-84. PubMed ID: 9829575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reproducibility of 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease.
    Hwang WJ; Yao WJ; Wey SP; Ting G
    J Nucl Med; 2004 Feb; 45(2):207-13. PubMed ID: 14960637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional morphometry of the striatum in Parkinson's disease on three-dimensional surface display of 123I-beta-CIT SPECT data.
    Ichise M; Kim YJ; Erami SS; Ballinger JR; Vines D; Tanaka F; Lang AE
    J Nucl Med; 1999 Apr; 40(4):530-8. PubMed ID: 10210210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
    Booij J; Tissingh G; Boer GJ; Speelman JD; Stoof JC; Janssen AG; Wolters EC; van Royen EA
    J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease.
    Scherfler C; Seppi K; Donnemiller E; Goebel G; Brenneis C; Virgolini I; Wenning GK; Poewe W
    Brain; 2005 Jul; 128(Pt 7):1605-12. PubMed ID: 15817519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging.
    Pirker W; Asenbaum S; Hauk M; Kandlhofer S; Tauscher J; Willeit M; Neumeister A; Praschak-Rieder N; Angelberger P; Brücke T
    J Nucl Med; 2000 Jan; 41(1):36-44. PubMed ID: 10647603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease.
    Asenbaum S; Brücke T; Pirker W; Podreka I; Angelberger P; Wenger S; Wöber C; Müller C; Deecke L
    J Nucl Med; 1997 Jan; 38(1):1-6. PubMed ID: 8998140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SPECT measurement of iodine-123-beta-CIT binding to dopamine and serotonin transporters in Parkinson's disease: correlation with symptom severity.
    Kim SE; Lee WY; Choe YS; Kim JH
    Neurol Res; 1999 Apr; 21(3):255-61. PubMed ID: 10319333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT.
    Booij J; Hemelaar TG; Speelman JD; de Bruin K; Janssen AG; van Royen EA
    J Nucl Med; 1999 May; 40(5):753-61. PubMed ID: 10319746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease.
    Seibyl JP; Marek KL; Quinlan D; Sheff K; Zoghbi S; Zea-Ponce Y; Baldwin RM; Fussell B; Smith EO; Charney DS; van Dyck C
    Ann Neurol; 1995 Oct; 38(4):589-98. PubMed ID: 7574455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT.
    Kim SE; Choi JY; Choe YS; Choi Y; Lee WY
    J Nucl Med; 2003 Jun; 44(6):870-6. PubMed ID: 12791812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SPECT-evaluation of the monoamine uptake site ligand [123I](1R)-2-beta-carbomethoxy-3-beta-(4-iodophenyl)-tropane ([123I]beta-CIT) in untreated patients with suspicion of Parkinson disease.
    Eising EG; Müller TT; Zander C; Kuhn W; Farahati J; Reiners C; Coenen HH
    J Investig Med; 1997 Oct; 45(8):448-52. PubMed ID: 9394097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction.
    Sakakibara R; Shinotoh H; Uchiyama T; Yoshiyama M; Hattori T; Yamanishi T
    J Neurol Sci; 2001 Jun; 187(1-2):55-9. PubMed ID: 11440745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
    Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I
    J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECT.
    Tissingh G; Bergmans P; Booij J; Winogrodzka A; van Royen EA; Stoof JC; Wolters EC
    J Neurol; 1998 Jan; 245(1):14-20. PubMed ID: 9457623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson's disease subjects.
    Kim HJ; Im JH; Yang SO; Moon DH; Ryu JS; Bong JK; Nam KP; Cheon JH; Lee MC; Lee HK
    J Nucl Med; 1997 Nov; 38(11):1703-11. PubMed ID: 9374337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.